Rhythm Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE, as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. IMCIVREE is approved by the Food and Drug Administration (FDA) for chronic weight management in adult and pediatric patients six years of age and older with monogenic or syndromic obesity due to proopiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1) or leptin receptor (LEPR) deficiency as determined by an FDA-approved test demonstrating variants in POMC, PCSK1, or LEPR genes that are interpreted as pathogenic, likely pathogenic, or of uncertain significance (VUS). In addition to setmelanotide, it has two earlier-stage investigational MC4R agonists in clinical development, RM-718, designed for weekly administration, and bivamelagon, an oral small molecule.
BörsenkürzelRYTM
Name des UnternehmensRhythm Pharmaceuticals Inc
IPO-datumOct 05, 2017
Gegründet am2013
CEO- -
Anzahl der mitarbeiter283
WertpapierartOrdinary Share
GeschäftsjahresendeOct 05
Addresse222 Berkeley Street
StadtBOSTON
BörseNASDAQ Global Market Consolidated
LandUnited States of America
Postleitzahl02116
Telefon18572644280
Websitehttps://rhythmtx.com/
BörsenkürzelRYTM
IPO-datumOct 05, 2017
Gegründet am2013
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten